Creo Medical Group PLC LTIP Awards and Issue of Equity (3952D)

TIDMCREO

RNS Number : 3952D

Creo Medical Group PLC

19 February 2020

Creo Medical Group plc

("Creo" the "Company" or the "Group")

LTIP Awards and Issue of Equity

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it is giving effect to the disclosure made in the Circular dated 4 December 2019, and has as of 18 February 2020, granted the following Directors ("Participants") an interest over 370,000 ordinary shares ("LTIP Shares") of 0.1 pence each in the capital of the Company ("Ordinary Shares"), representing approximately 0.2% of the enlarged issued share capital of the Company, pursuant to the Company's newly established Long Term Incentive Plan ("LTIP").

 
 Director           Position            LTIP Shares 
-----------------  ------------------  ------------ 
                    Chief Executive 
 Craig Gulliford     Officer              140,000 
                    Chief Technology 
 Chris Hancock       Officer              115,000 
                    Chief Finance 
 Richard Rees        Officer              115,000 
 

The Company has made an application for 7,000,000 new Ordinary Shares to be admitted to trading on AIM. These new Ordinary Shares will be held by the Company's Employee Benefit Trust ("EBT") and will be used to satisfy exercises of shares currently under option, as well as for future LTIP awards. The voting rights on these new Ordinary Shares will be exercisable by the trustee of the EBT ("Trustee") at its sole discretion.

The Participant and the Trustee jointly own the beneficial interest of the LTIP Shares. The Participant is entitled to any value above the Hurdle Price of GBP2.50 per share and the Trustee entitled to all value below the Hurdle Price. The Participant has also been granted an option to acquire the Trustee's beneficial interest in the LTIP shares, which vests three years after the acquisition date (subject to remaining in eligible employment) and the exercise of which is subject to a three-month holding period once vested.

Application will be made for 7,000,000 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will take place on 21 February 2020. Following the allotment and issue, the Company's issued share capital consists of 157,484,021 Ordinary Shares. The Company does not hold any shares in Treasury, as such the total number of shares in issue with voting rights is 157,484,021.

The above figure of 157,484,021 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

 
 Creo Medical Group plc                                     investors.creomedical.com 
 Richard Rees (CFO)                                               [phone] 
 
 Cenkos Securities plc                                            [phone] 
 Stephen Keys / Cameron MacRitchie 
  (NOMAD) 
 Michael Johnson / Russell 
  Kerr (Sales) 
 
 Walbrook PR Ltd                      Tel: [phone] or [e-mail] 
 Paul McManus / Lianne Cawthorne               Mob: [phone] 
                                                                              909 238 
 
 

The following notifications are intended to satisfy the Company's obligations under Article 19(3) of EU Regulation No 596/2014 (the Market Abuse Regulation).

 
    1       Details of the person discharging managerial responsibilities 
             / person closely associated 
    a)      Name                        1. Craig Gulliford 
                                         2. Chris Hancock 
                                         3. Richard Rees 
        -----------------------------  --------------------------------------------- 
    2       Reason for the notification 
        ---------------------------------------------------------------------------- 
    a)      Position/status             1. Chief Executive Officer 
                                         2. Chief Technology Officer 
                                         3. Chief Finance Officer 
        -----------------------------  --------------------------------------------- 
    b)      Initial notification        Initial notification 
             /Amendment 
        -----------------------------  --------------------------------------------- 
    3       Details of the issuer, emission allowance market participant, 
             auction platform, auctioneer or auction monitor 
        ---------------------------------------------------------------------------- 
    a)      Name                        Creo Medical Group plc 
        -----------------------------  --------------------------------------------- 
    b)      LEI                         213800H188ZDCWWXFA21 
        -----------------------------  --------------------------------------------- 
    4    Details of the transaction(s): section to be repeated 
          for (i) each type of instrument; (ii) each type of 
          transaction; (iii) each date; and (iv) each place 
          where transactions have been conducted 
        ---------------------------------------------------------------------------- 
    a)      Description of the          Ordinary shares of GBP0.001 each 
             financial instrument, 
             type of instrument 
 
            Identification code         GB00BZ1BLL44 
 
    b)      Nature of the transaction   Allocation of Ordinary Shares under 
                                         the Creo Medical Group plc LTIP 
                                         2020 
        -----------------------------  --------------------------------------------- 
    c)      Price(s) and volume(s) 
                                               ---------------  ------------ 
                                                Price(s) pence   Volume(s) 
                                               ---------------  ------------ 
                                                1. nil           1. 140,000 
                                                 2. nil           2. 115,000 
                                                 3. nil           3. 115,000 
                                               ---------------  ------------ 
 
    d)      Aggregated information 
 
            - Aggregated volume         N/A - single transaction 
 
            - Price 
 
    e)      Date of the transaction     18 February 2020 
        -----------------------------  --------------------------------------------- 
    f)      Place of the transaction    Outside a trading venue 
        -----------------------------  --------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCEAXAPFSLEEFA

(END) Dow Jones Newswires

February 19, 2020 02:00 ET (07:00 GMT)